LEGN
Legend Biotech's Q4 2025 Earnings Call Highlights: A Year of Milestones for CARVYKTI and Beyond
Legend Biotech, a leading cell therapy company, has made significant strides in the fourth quarter of 2025, according to its recent earnings call. The company reported strong sales and profitability numbers, with CARVYKTI net trade sales reaching $555 million, a 66% increase year-over-year. The success of CARVYKTI, Legend Biotech'
